CAMBRIDGE, England, January 8 /PRNewswire/ -- Crescendo Biologics
("Crescendo") today announces the appointment of Clive Dix as Chairman. Dr
Dix will work closely with Mike Romanos, Chief Scientific Officer of
Crescendo, to drive the development of the Company and its proprietary
antibody fragment technologies following the recent GBP4.5 million seed round
fundraising.